GLPBio

KF21213

Catalog No.: GC31217Purity:>98.00%

KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors.

Products are for research use only. Not for human use. We do not sell to patients.


KF21213
Cas No.: 155271-17-3
1mgQuote
Contact for Price
5mgQuote
Contact for Price
10mgQuote
Contact for Price
20mgQuote
Contact for Price

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors. KF21213 shows a high affinity for the adenosine A2A receptors (Ki=3.0 nM).

[11C]KF21213 as a PET ligand for mapping adenosine A2A receptors in the central nervous system (CNS). KF21213 shows a high affinity for the adenosine A2A receptors in vitro (Ki=3.0 nM) and a very low affinity for the A1 receptors (Ki>10,000 nM)[1].

The uptake of [11C]KF21213 by the striatum gradually increases for the first 15 min and then decreases. The uptake by the cortex and cerebellum is rapidly decreased after injection. Their levels are compatible with that in the blood. Consequently, the uptake ratios of striatum to cortex and striatum to cerebellum increases up to 8.6±1.6 and 10.5±2.1 (N=4), respectively, by 60 min. The striatal activity level of [11C]KF21213 is retained for the initial 5 min and then gradually decreased with time, whereas that of [11C]KF18446 rapidly decreases.The cerebellar activity of the two ligands rapidly decreases.The striatum-to-cerebellum uptake ratio for [11C]KF21213 gradually increases to 2.4 6 0.5 (N 5 3) by 50-60 min, whereas that for [11C]KF18446 increases for the first 10 min and remains constant (1.4±0.3, N=3, at 25-35 min)[1].

[1]. Wang WF, et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol. 2000 Aug;27(6):541-6.

Protocol

Kinase experiment:

The in vitro affinity of KF21213 for the adenosine A2A and A1 receptors is determined using the rat striatal membrane and [3H]CGS 21680 as a radioligand and the rat forebrain membrane and N6-[3H]cyclohexyladenosine, respectively. The assay is performed in the dark to prevent photo-isomerization[1].

Cell experiment:

Mice[1]Two groups of male ddY mice (30-39 g) are used. In the first group, [11C]KF21213 (1.1 MBq/36 pmol) is intravenously injected. They are killed by cervical dislocation at 5, 15, 30, and 60 min after injection (N=4 each). Blood is collected by heart puncture. The brain is removed and dissected into the striatum, cortex, and cerebellum. The regional brain uptake of radioactivity is measured as the percentage of injected dose per gram tissue (%ID/g). In the other group, [11C]KF21213 (1.1 MBq/21 pmol) is co-injected with one of the following adenosine receptor antagonists: A2A antagonists KF21213, KF17837, KF18446, and SCH 58261 and an A1 antagonist KF15372. The injected dose of KF21213 is 30 nmol and that of other antagonists is 50 nmol. The mice are killed at 15 min after injection (N=9 for control and N=4 for each of the other groups). The regional brain uptake of radioactivity is measured. Rat[1]PET measurement is performed in three rats with a model SHR-2000 camera with Z=2 mode, providing 14 slices at 3.25 mm intervals. The rat (240-300 g) is anesthetized with 0.02% isoflurane throughout the PET study. The anesthetized rat is positioned prone on a stereotaxic head holder made of polymethyl methacrylate. An incision is made on the scalp to locate the bregma, which is positioned at the tenth slice from caudal. After a transmission scan to correct for photon attenuation, the [11C]KF21213 (N=3) (43–56 MBq/1.2-1.9 nmol/kg body weight) or [11C]KF18446 (N=3) (50-55 MBq/1.8-4.9 nmol/kg body weight) is injected through the tail vein, and the time sequential tomographic scanning is performed for 60 min (20 frames by 30 sec and 50 frames by 1 min).

References:

[1]. Wang WF, et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol. 2000 Aug;27(6):541-6.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

CAS No.
155271-17-3
SMILES
O=C(N1C)N(C)C2=C(N(C)C(/C=C/C3=CC=C(OC)C(C)=C3C)=N2)C1=O
Molecular Formula
C19H22N4O3
Molecular Weight
354.4
Solubility
Soluble in DMSO
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for KF21213

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%